China Strengthens Safety Nets Following Pediatric Deaths, Testing Gene Therapy Fast-Track Regulation No. 818
Background
In the past two months, two children participating in different clinical trials in China died after receiving gene-editing treatments. This case has brought to light the structural risks of the Investigator-Initiated Trial (IIT) pathway, which has driven the rapid growth of China's biotech industry. IITs have widely been used as a channel to quickly secure human administration data by bypassing the formal approval process of the National Medical Products Administration (NMPA).
Indeed, the number of registered IITs in China's Cell and Gene Therapy (CGT) sector has grown steeply since 2015, surging 11-fold to 207 cases in 2023. Dai Jia Ling, CEO of PharmaDJ, evaluates IITs as tools that quickly provide evidence of efficacy before large-scale clinical trials. Conversely, the management and supervision system failed to keep pace with this speed. According to Iris Zhang, an attorney at Han Kun Law Offices, even though regulations stipulated that stem cell trials should only be conducted at Class 3A (tertiary) hospitals, insufficient on-site monitoring led to frequent unauthorized cell therapies and medical accidents at unauthorized institutions, such as private clinics.
Key Findings
As accidents continued, attention is turning to the new regulatory guideline, Decree No. 818, which the Chinese government abruptly implemented on May 1, 2026. Professor Hao Bin of Xi'an Jiaotong-Liverpool University stated that Decree No. 818 was enacted to strengthen clinical supervision of advanced biotechnology, including gene editing, cell therapy, and brain implants.
The new regulation strictly limits the eligibility to conduct high-risk advanced technology IITs to top-tier Class 3A hospitals. Health policy consultant Ruby Wang explained that this measure allows research only in institutions possessing top-level clinical personnel and patient safety nets. The supervision method has also been significantly overhauled. Previously, trials could begin with only approval from a hospital's ethics committee and registration with the National Health Commission (NHC); now, the NHC can conduct a secondary review and unilaterally suspend or cancel research. Attorney Aaron Gu of Han Kun Law Offices analyzed that a regulatory mechanism close to a de facto approval system has been established. Institutions conducting unauthorized trials face fines of millions of yuan, a three-year ban on research qualifications, and revocation of the lead physician's license, while a new path has also opened for companies to directly initiate Investigator-Initiated Trials (IITs).
Implications and Outlook
This reorganization signifies that Chinese biotech research, which was previously speed-oriented, has shifted toward patient safety and qualitative management. Lizzie Li, a researcher at the Asia Society Policy Institute, pointed out that consistent law enforcement is key. She explained that inadequate surveillance could lead to a loss of public trust, while excessive strictness could hinder technological progress.
As gene editing carries inherent risks of off-target mutations and immune rejection, reflections have emerged that basic safety verification should have been stricter for pediatric clinical trials. Moving forward, companies that fail to provide rigorous safety data are likely to face high barriers to entering Class 3A hospitals. The high-intensity disciplinary measures, such as the central government's power to suspend operations and revoke licenses, are interpreted as a decisive move to enhance the international credibility of Chinese biotech research. Attention is focused on whether the balance between patient safety and technological innovation can be achieved after overcoming initial confusion.
Nature, Published online: 08 September 2026; doi:10.1038/d41586-026-02407-6A new government policy seeks to balance innovation and safety.
The implementation of Article 818 is expected to completely reshape the collaboration model between clinical medical sites and the pharmaceutical industry. First, at clinical sites, high-risk gene editing procedures will be centralized in tertiary large hospitals equipped with intensive care units for critically ill patients and monitoring systems for severe adverse reactions. A pediatrician specializing in treating children with rare genetic diseases can safely administer medications according to standard protocols approved by the central government, while excluding the temptation of unverified procedures at unlicensed clinics.
In the biotech industry, a legal pathway has been secured to obtain Proof of Concept (PoC) data prior to the stage of formal Clinical Trial Application (CTA) approval. As companies can now directly act as research entities, the risk of disputes over research design and data ownership will significantly decrease. However, given the introduction of new regulations imposing fines of millions of yuan and revoking research eligibility, companies will undergo a strategic selection process to ensure that only substances meeting off-target cleavage verification and Good Manufacturing Practice (GMP) standards in the non-clinical stage are advanced into clinical trials in collaboration with Class III hospitals.